Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We show that the glial cell line-derived neurotrophic factor (GDNF) activates the PI3K/Akt-signaling pathway in human neuroblastoma cells that express functional Ret-receptor complexes.
|
12485836 |
2002 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We previously demonstrated that PI3K Class IIβ (PI3KC2β) and its regulator intersectin 1 (ITSN1) are highly expressed in primary NB tumors and cell lines.
|
25622909 |
2015 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesize that VEGF will up-regulate survivin, a member of the IAP family of anti-apoptotic proteins, via the PI3K/Akt cell signaling pathway in human neuroblastoma cells.
|
15882878 |
2005 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of neuroblastoma cells with the dual PI3K/mTOR inhibitor PI-103 activated FOXO3a and triggered apoptosis.
|
23378341 |
2013 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This decline in mTOR activity was accompanied by an increase in phosphoinositide 3 kinase (PI3K)/Akt activity and a parallel increase in p-tau (Ser<sup>396</sup>) but not p-tau (Ser<sup>262</sup>) in differentiated SH-SY5Y neuroblastoma cells.
|
29398519 |
2018 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that repression of Survivin by FKHRL1 facilitates FKHRL1-induced apoptosis and sensitizes to cell death induced by DNA-damaging agents, which supports the central role of PI3K-PKB-FKHRL1 signaling in drug resistance of human NB.
|
19211844 |
2009 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results show that the ERas/PI3K pathway may provide resistance to chemotherapy and promote transforming activity in neuroblastoma.
|
20811723 |
2010 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The way of PI3K/AKT/mTOR pathway activation in neuroblastoma (NB) is not well established.
|
21225506 |
2010 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to determine whether the phosphatidylinositol 3-kinase (PI3K)/Akt pathway can alter the expression of survivin and facilitate tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in neuroblastoma cells.
|
15065019 |
2004 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K inhibitor PI103 cooperates with TRAIL to synergistically induce apoptosis (combination index < 0.1), to suppress clonogenic survival, and to reduce tumor growth in a neuroblastoma in vivo model.
|
21355080 |
2011 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting MYCN, as a novel effector of PI3K-mediated angiogenesis, has significant potential for the treatment of highly vascularized, malignant NB.
|
18278068 |
2008 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SF1126 inhibits BRD4 bromodomain binding to acetylated lysine residues with histone H3 as well as PI3K activity in the MYCN amplified neuroblastoma cell line IMR-32.
|
28881723 |
2017 |
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Protective Effects of Fisetin Against 6-OHDA-Induced Apoptosis by Activation of PI3K-Akt Signaling in Human Neuroblastoma SH-SY5Y Cells.
|
29204750 |
2018 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway.
|
29352113 |
2018 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI103 combined doxorubicin significantly inhibits the growth of established NB tumors, induced apoptosis of tumor cells, and improved the survival of mice in vivo Taken together, our findings suggest that PI3K inhibition seems to be a promising option to sensitize tumor cells for chemotherapy in NB, which may be effective in the treatment of NBs.
|
26224681 |
2016 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacological inhibition of PI3K greatly reduced the ability of PDGF-BB to block gp120 IIIB-mediated apoptosis and cell death in human neuroblastoma cells.
|
18973553 |
2008 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Palmitic acid stimulates energy metabolism and inhibits insulin/PI3K/AKT signaling in differentiated human neuroblastoma cells: The role of mTOR activation and mitochondrial ROS production.
|
28919254 |
2017 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that targeting PI3K and mTORC2 in aggressive neuroblastomas with an immature phenotype may improve therapeutic efficacy.
|
26432405 |
2015 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous studies have demonstrated that PI3K/AKT signaling is critical for the oncogenic transformations induced by gastrin-releasing peptide (GRP) and its receptor, GRP-R, in neuroblastoma.
|
23468863 |
2013 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data also suggest that the phosphoinositide 3-kinase (PI3K) inhibitors may provide new opportunities for the treatment of the <i>MYCN</i>-amplified neuroblastoma subtype.
|
29137381 |
2017 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neuroprotection of miR-214 against isoflurane-induced neurotoxicity involves the PTEN/PI3K/Akt pathway in human neuroblastoma cell line SH-SY5Y.
|
31704096 |
2019 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, inhibitors of PI3K/mTOR and GLI signaling reduced neuroblastoma cell growth, but no additional growth inhibitory effects were detected when the two classes of drugs were combined.
|
25134527 |
2014 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
|
25228590 |
2014 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of the PI3K/Akt pathway does not increase the sensitivity of neuroblastoma cell lines to TRAIL-induced apoptosis.
|
16769337 |
2006 |
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we investigated the phosphorylation status of key proteins in the PI3K/AKT/mTOR pathway and the effects of the mTOR inhibitors rapamycin and CCI-779 on neuroblastoma tumorigenesis.
|
18026138 |
2008 |